Haleon plc — Form 6-K Summary
Filing date: 27 July 2022. The filing contains Haleon’s trading update for the six months ended 30 June 2022. Haleon had recently demerged from GSK, listed on the London Stock Exchange on 18 July 2022, and began regular NYSE trading on 22 July 2022.
Business context and reporting period
Haleon is a global consumer-health company operating across Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, and Digestive Health and Other. The company employs more than 22,000 people across 170 markets. Full unaudited half-year results were scheduled for 19 September 2022.
Key financial metrics
| Metric | H1 2022 | H1 2021 | Change |
|---|---|---|---|
| Revenue | £5,188m | £4,575m | 13.4% |
| Organic revenue growth | 11.6% | Not clearly provided for the comparable period in this update | — |
| Organic growth contribution from price | 3.7% | — | — |
| Organic growth contribution from volume/mix | 7.9% | — | — |
| Q2 revenue | £2,561m | £2,269m | 12.9% |
| Q2 organic revenue growth | 7.5% | — | — |
The filing does not provide H1 2022 IFRS profit, adjusted operating profit, cash flow, balance-sheet liquidity, or net debt figures. FY2021 adjusted operating margin was 22.8%; H1 2021 adjusted operating profit was £983m and adjusted operating margin was 21.5%, but the filing does not provide the corresponding H1 2022 profit figure.
Revenue by category and geography
| Category | H1 2022 revenue | Reported change | Organic change |
|---|---|---|---|
| Oral Health | £1,438m | 5.7% | 5.1% |
| VMS | £816m | 16.2% | 11.9% |
| Pain Relief | £1,248m | 14.2% | 11.7% |
| Respiratory Health | £683m | 50.1% | 46.7% |
| Digestive Health and Other | £1,003m | 3.9% | 3.5% |
| Geography | H1 2022 revenue | Reported change | Organic change |
|---|---|---|---|
| North America | £1,873m | 17.4% | 10.4% |
| EMEA and LatAm | £2,069m | 8.7% | 12.1% |
| APAC | £1,246m | 15.7% | 12.3% |
Material changes versus the prior comparable period
- H1 reported revenue increased 13.4%, with broad-based organic growth of 11.6% driven by both pricing and volume/mix.
- Q2 organic growth moderated to 7.5%. Volume was adversely affected by approximately 2% from the reversal of a Q1 system cutover benefit.
- Respiratory Health was the strongest category, reflecting a strong cold and flu season and the Omicron wave. Respiratory performance contributed approximately 4% to group H1 organic growth.
- Power brands grew 13.4% organically, with particularly strong performance from Panadol, Theraflu, Otrivin, Advil, and Centrum.
- E-commerce represented 9% of total sales and grew at a high-teens rate.
- Asia-Pacific organic growth included an approximately 2% one-off benefit related to separation-related distribution changes in Vietnam.
Debt, liquidity, outlook, and risks
- On 13 July 2022, Haleon drew £1,490m under a term loan, net of £4m of transaction costs. The funds were used to partially settle dividends paid to GSK and Pfizer.
- On 13 July 2022, Haleon paid a £53m balancing dividend to GSK, a £10,401m pre-separation cash dividend, and a £603m final sweep dividend to GSK and Pfizer. The filing does not provide a post-transaction net debt or liquidity balance.
- FY2022 organic revenue growth guidance was raised to 6%–8% following first-half momentum.
- FY2022 adjusted operating margin is expected to be slightly below FY2021’s 22.8% on a constant-currency basis. Growth, Pfizer synergies, pricing, supply efficiencies, and slightly favorable currency are expected to largely offset £175m–£200m of standalone costs, investment, inflationary pressure, and the impact of Russia and Ukraine.
- Medium-term guidance was reiterated: 4%–6% annual organic revenue growth, sustainable moderate adjusted operating margin expansion at constant currency, and net debt to EBITDA below 3 times by the end of 2024.
- Key uncertainties include inflation, foreign-exchange movements, the Russia-Ukraine conflict, COVID-19 effects and related lockdowns, separation and standalone costs, supply conditions, retailer inventory changes, and the normalization of unusually strong respiratory demand.
- Adjusted results exclude items including intangible amortization and impairment, restructuring, transaction-related, separation and admission costs, and disposals and other items. Accordingly, adjusted measures are not a complete substitute for IFRS results.
Important facts for investors to verify
- Verify the full half-year results when released, particularly IFRS and adjusted operating profit, cash flow, net debt, liquidity, and reconciliation items for H1 2022.
- Assess the sustainability of respiratory, Pain Relief, and VMS growth after the post-COVID and strong cold-and-flu-season effects subside.
- Confirm the final debt structure, interest costs, leverage, and liquidity after the £1,490m term-loan draw and the large separation-related dividends.
- Evaluate whether the expected pricing and Pfizer synergies offset inflation, standalone costs, continued investment, and Russia-Ukraine impacts.
- Review the treatment and magnitude of separation, admission, restructuring, transaction, and intangible-related adjustments when comparing adjusted results with IFRS performance.